The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Linezolid: The First Oxazolidinone Antimicrobial
Abstract
Linezolid is the first of a new class of antimicrobial agents, the oxazolidinones, to be approved for clinical use in the United States and elsewhere. The drug is a totally synthetic compound, which lessens the likelihood of naturally occurring resistance mechanisms. It has excellent activity against virtually all important gram-positive pathogens, including methicillin-resistant staphylococci, penicillin-resistant pneumococci, macrolide-resistant streptococci, and vancomycin-resistant enterococci. Development of resistance to the compound has been infrequent thus far. Linezolid is 100% bioavailable, so it can be given in equal doses orally or parenterally. Its elimination half-life allows dosing twice per day, and alteration of drug dosage is not required in patients with impaired renal or hepatic function. Linezolid has approved indications for skin and soft tissue infections; lower respiratory tract infections; and vancomycin-resistant Enterococcus faecium infections, including cases with concurrent bacteremia. The drug has an acceptable profile of adverse events, but reversible myelosuppression has occurred in patients receiving high doses for more than 2 weeks.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gold, H. S., & Moellering, R. C. (1996) · New England Journal of Medicine · doi:10.1056/nejm199611073351907 · Cited by 1,070
Self-citationLinezolid resistance in a clinical isolate of Staphylococcus aureus
Tsiodras, S., Gold, H. S., Sakoulas, G., Eliopoulos, G. M., Wennersten, C., Venkataraman, L., Moellering, R. C., & Ferraro, M. J. (2001) · The Lancet · doi:10.1016/s0140-6736(01)05410-1 · Cited by 1,033
Self-citationThe Oxazolidinone Linezolid Inhibits Initiation of Protein Synthesis in Bacteria
Swaney, S. M., Aoki, H., Ganoza, M. C., & Shinabarger, D. L. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.12.3251 · Cited by 555
Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid
Gonzales, R. D., Schreckenberger, P. C., Graham, M. B., Kelkar, S., DenBesten, K., & Quinn, J. P. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04376-2 · Cited by 542
In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents
Zurenko, G. E., Yagi, B. H., Schaadt, R. D., Allison, J. W., Kilburn, J. O., Glickman, S. E., Hutchinson, D. K., Barbachyn, M. R., & Brickner, S. J. (1996) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.40.4.839 · Cited by 461
Rubinstein, E., Cammarata, S. K., Oliphant, T. H., Wunderink, R. G., & the Linezolid Nosocomial Pneumonia Study Group (2001) · Clinical Infectious Diseases · doi:10.1086/318486 · Cited by 440
Prystowsky, J., Siddiqui, F., Chosay, J., Shinabarger, D. L., Millichap, J., Peterson, L. R., & Noskin, G. A. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.7.2154-2156.2001 · Cited by 302
Lin, A. H., Murray, R. W., Vidmar, T. J., & Marotti, K. R. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.10.2127 · Cited by 261
Stevens, D. L., Smith, L. G., Bruss, J. B., McConnell-Martin, M. A., Duvall, S. E., Todd, W. M., & Hafkin, B. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.12.3408-3413.2000 · Cited by 242
Diekema, D. J., & Jones, R. N. (2000) · Drugs · doi:10.2165/00003495-200059010-00002 · Cited by 226
Cited by
Liu, C., Bayer, A., Cosgrove, S. E., Daum, R. S., Fridkin, S. K., Gorwitz, R. J., Kaplan, S. L., Karchmer, A. W., Levine, D. P., Murray, B. E., et al. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/ciq146 · Cited by 4,191
Mandell, L. A., Bartlett, J. G., Dowell, S. F., File, T. M., Musher, D. M., & Whitney, C. (2003) · Clinical Infectious Diseases · doi:10.1086/380488 · Cited by 1,004
Antibiotic Resistance and the MRSA Problem
Vestergaard, M., Frees, D., & Ingmer, H. (2019) · Microbiology Spectrum · doi:10.1128/microbiolspec.gpp3-0057-2018 · Cited by 490
Urea Derivatives in Modern Drug Discovery and Medicinal Chemistry
Ghosh, A. K., & Brindisi, M. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01541 · Cited by 401
Antimicrobial Resistance to Linezolid
Meka, V. G., & Gold, H. S. (2004) · Clinical Infectious Diseases · doi:10.1086/423841 · Cited by 309
Metadata
- Authors
- Moellering, R. C.
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2003-01-21
- Volume
- 138
- Issue
- 2
- Pages
- 135-142
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W4254122983
- Cited by
- 455
- References
- 28
- FWCI
- 18.95
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Linezolid: The First Oxazolidinone Antimicrobial. https://app.cochat.ai/papers/10.7326/0003-4819-138-2-200301210-00015
- The paper
- Moellering, R. C. (2003). Linezolid: The First Oxazolidinone Antimicrobial. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-138-2-200301210-00015
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.